Therapeutic Areas: Ophthalmology

Choose Therapeutic Area
Oncology
Cardiology
Ophthalmology
Neurology
Endocrinology
Gastroenterology
Dermatology
Urology
Infectious diseases incl. Covid-19
Psychiatry
Rare diseases
Cromos Pharma has vast experience in providing a wide range of CRO services to support the development of new treatments and interventions for various eye-related disorders

We have specialized expertise in designing and conducting clinical trials for ophthalmic drugs, medical devices, and surgical procedures. Our experience includes working with a range of ophthalmic conditions, including age-related macular degeneration, diabetic retinopathy, glaucoma, and dry eye syndrome.

We offer our sponsors support in ophthalmologic clinical trial design. Cromos Pharma works closely with its clients to develop clinical trial protocols that are scientifically rigorous and easily meet regulatory requirements. We help our sponsors to identify appropriate endpoints and outcome measures to assess both safety and efficacy of their investigational products. We are experts in creating investigator brochures and other regulatory documents. We can also provide support for publications and presentations that address clinical trial results.

Cromos Pharma has extensive knowledge of international regulatory requirements for ophthalmologic clinical trials and can help its clients navigate the complex regulatory landscape. We provide support for regulatory submissions in EU via CTIS and in the US, including INDs, NDAs, MAAs, and BLAs, and can help our clients prepare for meetings with regulatory agencies.

Cromos Pharma provides a wide range of specialized services to support the development of new treatments and therapies for eye-related disorders. Our expertise in clinical trial design, data management and analysis, regulatory support, medical writing, and quality assurance can help our clients bring new ophthalmic products to market more efficiently and effectively.

Our ophthalmic experience includes:
    • Aged-related macular degeneration
    • Cataracts
    • Conjunctivitis
    • Contact lenses
    • Diabetic macular edema
    • Diabetic retinopathy
    • Dry eye syndrome
    • Geographic atrophy
    • Glaucoma
    • Post-operative ocular inflammation
Cromos Pharma Ophthalmology experience in the last five years
12,000
Patients
40
Studies
1,500
Clinical Sites
our Success story
A Phase III, randomized, double-blind trial in patients with Diabetic Macular Edema
Click to openclose
Why Cromos Pharma
  • We are the only CRO to offer “No Patients, No Payment” risk sharing program, where the sponsor pays only if we deliver on our milestones.
  • We have the scientific and clinical expertise to support your clinical studies, from early to late phase, from single- to multi-country execution strategies.
  • By leveraging our international expertise, we deliver unparalleled results through diligent feasibility analysis, rapid startup, and accelerated recruitment, while utilizing proactive risk management strategies and maintaining the highest data quality.
  • Our team has vast expertise in organizing scientific advisory board meetings of key opinion leaders, clinicians, and industry stakeholders.

TO FIND OUT MORE

INQUIRY@CROMOSPHARMA.COM

more therapeutics